Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 12, 2026
- Evommune licensed EVO570 from Hinova for $30 million upfront and raised approximately $30 million through a private placement, reporting $262.3 million in cash, cash equivalents and investments and cash runway into 2H 2029.
- 10-Q report · filed Nov 12, 2026
- Evommune discontinued EVO756 development in CSU and AD after Phase 2b trials missed endpoints, while migraine development continues. It reported $262.3 million in liquidity and expects funding into the second half of 2029.
The audio replay and transcript follow the call.